NCT05071898View on ClinicalTrials.gov

Pharmacogenetics of Response to GLP1R Agonists

PHASE1RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2027

Conditions
ObesityDiabetes Type 2
Interventions
DRUG

Semaglutide Pen Injector [Ozempic]

Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.

Trial Locations (1)

17602

RECRUITING

Amish Research Clinic, Lancaster

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER